tailieunhanh - The platelet contribution to cancer progression

The diagnosis of breast cancer, the most common type of cancer amongAmerican women, elicits greater distress than any other diagnosis, regardless of prognosis (National Cancer Institute [NCI], 1997; Stechlin & Beach, 1966; Vinokur, Threatt, Caplan, & Zimmerman, 1989). The aim of this article is to shed more light on the relationship between quality of life and aspects of the psychosocial experience for women with breast cancer. Further, we hope to provide information that will help health care professionals better understand quality of life and psychosocial issues for women with breast cancer in attempt to aug- ment clinical interventions and care. Ultimately, we suggest that the biomedical model. | Journal of Thrombosis and Haemostasis 9 237-249 DOI REVIEW ARTICLE The platelet contribution to cancer progression N. M. BAMBACE and C. E. HOLMES Division of Hematology and Oncology Department of Medicine University of Vermont Burlington VT USA To cite this article Bambace NM Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011 9 237-49. Summary. Traditionally viewed as major cellular components in hemostasis and thrombosis the contribution of platelets to the progression of cancer is an emerging area of research interest. Complex interactions between tumor cells and circulating platelets play an important role in cancer growth and dissemination and a growing body of evidence supports a role for physiologic platelet receptors and platelet agonists in cancer metastases and angiogenesis. Platelets provide a procoagulant surface facilitating amplification of cancer-related coagulation and can be recruited to shroud tumor cells thereby shielding them from immune responses and facilitate cancer growth and dissemination. Experimental blockade of key platelet receptors such as GP1b IX V GPIIbIIIa and GPVI has been shown to attenuate metastases. Platelets are also recognized as dynamic reservoirs of proangiogenic and anti-angiogenic proteins that can be manipulated pharmacologically. A bidirectional relationship between platelets and tumors is also seen with evidence of tumor conditioning of platelets. The platelet as a reporter of malignancy and a targeted delivery system for anticancer therapy has also been proposed. The development of platelet inhibitors that influence malignancy progression and clinical testing of currently available antiplatelet drugs represents a promising area of targeted cancer therapy. Keywords angiogenesis cancer metastases platelets TCIPA. Introduction Tumor cells interact with all major components of the hemostatic system including platelets. Platelets and platelet activation have .